Overlapping peptide-binding specificities of HLA-B27 and B39: Evidence for a role of peptide supermotif in the pathogenesis of spondylarthropathies

Arthritis and Rheumatism

Volumn 42, Issue 1, 1999, Pages 175-181

  Sobao, Yuji ^a,b   Tsuchiya, Naoyuki ^c,d   Takiguchi, Masafumi ^a   Tokunaga, Katsushi ^c  

^a KUMAMOTO UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN; HLA B27 ANTIGEN; HLA B39 ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CROSS REACTION; GENETIC TRANSFECTION; HLA SYSTEM; HYDROPHOBICITY; LIGAND BINDING; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SPONDYLOARTHROPATHY;

AMINO ACID SEQUENCE; ANTIBODY SPECIFICITY; BINDING SITES, ANTIBODY; CROSS REACTIONS; GENES, OVERLAPPING; HLA-B ANTIGENS; HLA-B27 ANTIGEN; HUMANS; JOINT DISEASES; PEPTIDES; PROTEIN BINDING; SPINAL DISEASES; TRANSFECTION;

EID: 0032896385     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(199901)42:1<175::AID-ANR21>3.0.CO;2-7     Document Type: Article

References (40)

1. Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgcnic rats expressing HLA-B27 and human β2m: an animal model of HLA-B27-associated human disorders. Cell 1990;63:1099-112.
2. 2-microglobulin: a model of human spondyloarthropathies. J Exp Med 1995;182: 1153-8.
3. Rubin LA, Amos CI, Wade JA, Martin JR, Bale SJ, Little AH, et al. Investigating the genetic basis for ankylosing spondylitis: linkage studies with the major histocompatibility complex region. Arthritis Rheum 1994;37:1212-20.
4. Feltkamp TEW, Khan MA, López de Castro JA. The pathogenetic role of HLA-B27. Immunol Today 1996;17:5-7.
5. Madden DR, Gorga JC, Strominger JL, Wiley DC. The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC. Cell 1992;70:1035-48.
6. Davenport MP, Hill AVM. Peptides associated with MHC class I and class II molecules. In: Browning MJ, McMichael AJ, editors. HLA and MHC: genes, molecules and function. Oxford: BIOS Scientific Publishers Ltd; 1996. p. 277-308.
7. Yamaguchi A, Tsuchiya N, Mitsui H, Shiota M, Ogawa A, Tokunaga K, et al. Association of HLA-B39 with HLA-B27-negative ankylosing spondylitis and pauciarticular juvenile rheumatoid arthritis in Japanese patients: evidence for a role of the peptide-anchoring B pocket. Arthritis Rheum 1995;38:1672-7.
8. Falk K, Rötzschke O, Takiguchi M, Gnau V, Stevanović S, Jung G, et al. Peptide motifs of HLA-B38 and B39 molecules. Immunogenetics 1995;41:162-4.
9. Takamiya Y, Schönbach C, Nokihara K, Yamaguchi M, Ferrone S, Kano K, et al. HLA-B*3501-peptide interactions: role of anchor residues of peptides in their binding to HLA-B*3501 molecules. Int Immunol 1994;6:255-61.
10. Rötzschke O, Falk K, Stevanović S, Gnau V, Jung G, Rammensee H-G. Dominant aromatic/aliphatic C-terminal anchor in HLA-B*2702 and B*2705 peptide motifs. Immunogenetics 1994;39: 74-7.
11. Jardetzky TS, Lane WS, Robinson RA, Madden DR, Wiley DC. Identification of self peptides bound to purified HLA-B27. Nature 1991;353:326-9.
12. Kato N, Karaki S, Kashiwase K, Muller C, Akaza T, Juji T, et al. Molecular analysis of HLA-B39 subtypes. Immunogenetics 1993; 37:212-6.
13. Tanabe M, Sekimata M, Ferrone S, Takiguchi M. Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with HLA class I α3 domain. J Immunol 1992;148:3202-9.
14. Kikuchi A, Sakaguchi T, Miwa K, Takamiya Y, Rammensee H-G, Kaneko Y, et al. Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket. Immunogenetics 1996;43:268-76.
15. Sakaguchi T, Ibe M, Miwa K, Kaneko Y, Yokota S, Tanaka K, et al. Binding of 8-mer to 11-mer peptides carrying the anchor residues to slow assembling HLA class I molecules (HLA-B*5101). Immunogenetics 1997;45:259-65.
16. López-Larrea C, Gonzalez-Roces S, Alvarez V. HLA-B27 structure, function, and disease association. Curr Opin Rheumatol 1996;8:296-308.
17. Boisgérault F, Tieng V, Stolzenberg MC, Dulphy N, Khalil I, Tamouza R, et at. Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants: implications for susceptibility to spondylarthropathics. J Clin Invest 1996;98:2764-70.
18. Wen J, Wang J, Kuipers JG, Huang F, Williams KM, Raybourne RB, et al. Analysis of HLA-B*2705 peptide motif, using T2 cells and monoclonal antibody ME1. Immunogenetics 1994;39:444-6.
19. Tanigaki N, Fruci D, Vigneti E, Starace G, Rovero P, Londei M, et al. The peptide binding specificity of HLA-B27 subtypes. Immunogenetics 1994;40:192-8.
20. Galocha B, Lamas JR, Villadangos JA, Albar JP, López de Castro JA. Binding of peptides naturally presented by HLA-B27 to the differentially disease-associated B*2704 and B*2706 subtypes, and to mutants mimicking their polymorphism. Tissue Antigens 1996; 48:509-18.
21. Simmons WA, Summerfield SG, Roopenian DC, Slaughter CA, Zuberi AR, Gaskell SJ, et al. Novel HY peptide antigens presented by HLA-B27. J Immunol 1997;159:2750-9.
22. Fiorillo MT, Meadows L, D'Amato M, Shabanowitz J, Hunt DF, Appella E, et al. Susceptibility to ankylosing spondylitis correlates with the C-terminal residue of peptides presented by various HLA-B27 subtypes. Eur J Immunol 1997;27:368-73.
23. Tieng V, Dulphy N, Boisgérault F, Tamouza R, Charron D, Toubert A. HLA-B*2707 peptide motif: Tyr C-terminal anchor is not shared by all disease-associated subtypes. Immunogenetics 1998;47:103-5.
24. Garcia F, Marina A, López de Castro JA. Lack of carboxyl-terminal tyrosine distinguishes the B*2706-bound peptide repertoire from those of B*2704 and other HLA-B27 subtypes associated with ankylosing spondylitis. Tissue Antigens 1997;49:215-21.
25. López-Larrcea C, Sujirachato K, Mehra NK, Chiewsli P, Isarangkura D, Kanga U, et al. HLA-B27 subtypes in Asian patients with ankylosing spondylitis: evidence for new associations. Tissue Antigens 1995;45:169-76.
26. Ren EC, Koh WH, Sim D, Bocy ML, Wee GB, Chan SH. Possible protective role of HLA-B*2706 or ankylosing spondylitis. Tissue Antigens 1997;49:67-9.
27. Nasution AR, Mardjuadi A, Kunmartini S, Suryadhana NG, Sctyohadi B, Sudarsono D, et al. HLA-B27 subtypes positively and negatively associated with spondyloarthropathy. J Rheumatol 1997;24:1111-4.
28. Gonzalez-Roces S, Alvarez MV, Gonzalez S, Dieye A, Makni H, Woodfield DG, et al. HLA-B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens 1997;49: 116-23.
29. D'Amato M, Fiorillo MT, Carcassi C, Mathieu A, Zuccarelli A, Bitti PP, et al. Relevance of residue 116 of HLA-B27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 1995; 25:3199-201.
30. Khan MA, Kushner I, Braun WE. B27-negative HLA-Bw16 in ankylosing spondylitis [letter]. Lancet 1978;1:1370-1.
31. Hall PJ, Burman SJ, Laurent MR, Briggs DC, Venning HE, Leak AM, et al. Genetic susceptibility to early onset pauciarticular juvenile chronic arthritis: a study of HLA and complement markers in 158 British patients. Ann Rheum Dis 1986;45:464-74.
32. Salvarani C, Macchioni P, Crcmonesi T, Mantovani W, Battistel B, Rossi F, et al. The cervical spine in patients with psoriatic arthritis: a clinical, radiological and immunogenetic study. Ann Rheum Dis 1992;51:73-7.
33. Kobayashi S, Tanaka M, Tamura N, Hashimoto H, Hirose S. Reactive arthritis induced by tonsillitis [abstract]. Arthritis Rheum 1992;35 Suppl 9:S244.
34. Kobayashi S, Tamura T, Ichikawa G, Takasaki Y, Hashimoto H. Reactive arthritis induced by Pseodomonas aeruginosa. Clin Rheumatol 1996;15:516-20.
35. Brown M, Bunce M, Calin A, Darke C, Wordsworth P. HLA-B associations of HLA-B27 negative ankylosing spondylitis: comment on the article by Yamaguchi et al [letter]. Arthritis Rheum 1996;39:1768-9.
36. Awada H, Baddoura R, Naman R, Klayme S, Mansour I, Tamouza R, et al. Weak association between HLA-B27 and the spondylarthropathies in Lebanon. Arthritis Rheum 1997;40:388-9.
37. Robinson WP, van der Linden SM, Khan MA, Rentsch H-U, Cats A, Russell A, et al. HLA-Bw60 increases susceptibility to ankylosing spondylitis in HLA-B27+ patients. Arthritis Rheum 1989;32: 1135-41.
38. Brown MA, Kennedy LG, MacGregor AJ, Drake C, Duncan E, Shatford JL, et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis Rheum 1997;40:1823-8.
39. Falk K, Rötzschke O, Takiguchi M, Gnau V, Stevanović S, Jung G, et al. Peptide motifs of HLA-B58, B60, B61 and B62 molecules. Immunogenetics 1995;41:165-8.
40. Sidney J, Grey HM, Kubo RT, Sette A. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 1996;17:261-6.